VOVirginia Wedell Osborn

Virginia Wedell Osborn

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Virginia Wedell Osborn has a total of 78 co-authors. Here are the top co-authors by number of shared publications:

  • Anna Lee

    Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas

    16 shared publications
  • David Schreiber

    Department of Radiation Oncology, SUNY Downstate Medical Center, 450 Clarkson Avenue, Mail Stop #1211, Brooklyn, NY, 11203, USA

    15 shared publications
  • David Schwartz

    Department of Veterans Affairs, New York Harbor Healthcare System, New York, NY, USA; SUNY Downstate Medical Center, Brooklyn, NY, USA

    14 shared publications
  • Joseph Safdieh

    Department of Radiation Oncology, SUNY Downstate Medical Center, Brooklyn, NY, USA; Department of Veterans Affairs, New York Harbor Healthcare System, Brooklyn, NY, USA

    8 shared publications
  • Babak Givi

    Department of Otolaryngology—Head and Neck Surgery NYU Langone Health New York New York USA

    4 shared publications
  • Andrew T. Wong

    Department of Radiation Oncology, SUNY Downstate Medical Center, Brooklyn, NY - USA

    3 shared publications

Latest Publications

  • Adapting to the Virtual World: An Analysis of Remote Work Policies in Academic Radiation Oncology

    by Sara Beltran Ponce, Amy LoTemplio, Erin Kaya, Katie Lichter, Shradda M. Dalwadi, Sumi Sinha, Lois Wairiri, William Stadtlander, Mary McGunigal, Reshma Jagsi, et al.

    Objective: The COVID-19 pandemic led to a shift from traditional work environments to working from home (WFH). The specific benefits and challenges of WFH in radiation oncology (RO) are currently unknown. To address this gap in knowledge, a survey-based study was conducted to assess WFH policies and perceptions of their impact, as well as explore the role of departmental gender composition in remote work policies. Materials and Methods: Faculty and residents were randomly selected from the 92 American College of Graduate Medical Education-accredited RO residency programs. Descriptive statistics were generated for responses overall and separately among faculty and residents for demographic responses. They were also generated for responses relating to remote policy among departments with at least one-third female faculty/residents and those with less than one-third female faculty/residents. Associations between responses and groups were assessed using chi-square or Fisher exact tests for categorical responses and Wilcoxon rank-sum tests for numerical responses. Results: Although 58.6% of faculty and 59.1% of residents perceived a negative or somewhat negative impact of WFH on patient satisfaction, the majority (> 51%) had positive perceptions of impact on all other measured outcomes, including their time with children, time with partner, time with other family members, and their personal wellness. Additionally, the current study revealed that 93.4% (n = 57) of departments comprised of more than one-third women had WFH policies in place, while only 84.2% (n = 64) of departments comprised of fewer than one-third female members had such policies. Conclusion: These findings highlight the importance of diverse input from all genders as departments implement WFH policies. Further research should explore the durability of changes in workplace flexibility and how they may impact gender disparities within RO.


  • Prognostic significance of human papillomavirus and Epstein‐Bar virus in nasopharyngeal carcinoma

    by Nipun Verma, Suchit Patel, Virginia Osborn, Sean McBride, Nadeem Riaz, Anna Lee, Nora Katabi, Eric Sherman, Nancy Y. Lee, Chiaojung J. Tsai

    Background: The clinical significance of Epstein‐Barr virus (EBV) and human papillomavirus (HPV) infection in nasopharyngeal carcinoma (NPC) is unclear.Methods: Three hundred and forty three patients with NPC diagnosed between 1998 and 2017 and treated at our institution were included. Chi‐square was used to identify characteristics associated with viral status. Kaplan‐Meier methods were used to estimate overall survival (OS) and Cox proportional regression was used to identify prognostic factors.Results: Patients with HPV‐associated NPC were more likely to have a positive smoking history and to present at a higher T classification. At a median follow‐up time of 59.9 months (range: 0.1‐222.4 months), there were no differences in OS (P = .198), time to local failure (LF, P = .403), or time to distant metastasis (DM, P = .849) between the viral subgroups. Older age (hazard ratio [HR]: 2.242, 95% confidence interval [CI] 1.374‐3.659, P = .001) and higher overall stage (HR: 2.047, 95% CI 1.235‐3.391, P = .005) were prognostic for worse OS.Conclusion: In our population, viral status was not prognostic for OS, LF, or DM.


  • A Survey Study of Female Radiation Oncology Residents’ Experiences to Inform Change

    by Virginia W. Osborn, Kaleigh Doke, Kent A. Griffith, Rochelle Jones, Anna Lee, Genevieve Maquilan, Adrianna Henson Masters, Ashley A. Albert, Laura L. Dover, Lindsay L. Puckett, et al.


  • Patterns of Care and Survival Outcomes in the Treatment of Anal Melanoma

    by Jaffer Naqvi, Anna Lee, Ariel Lederman, Ami Kavi, Virginia W. Osborn, David Schreiber

    Anal mucosal melanoma is an uncommon malignancy of the anal canal, with few large studies available to establish clear trends in the treatment modalities presently available. The primary goal of this study was to identify the patterns of care in the treatment of anal melanoma and secondarily to determine outcomes.


  • Open Access

    #WomenWhoCurie: Leveraging Social Media to Promote Women in Radiation Oncology

    by Ashley A. Albert, Miriam A. Knoll, Kaleigh Doke, Adrianna Masters, Anna Lee, Laura Dover, Courtney Hentz, Lindsay Puckett, Chelain R. Goodman, Virginia W. Osborn, et al.


  • Open Access

    Association of Nadir Prostate-specific Antigen >0.5 ng/mL after Dose-escalated External Beam Radiation with Prostate Cancer-specific Endpoints

    by Niki Sheth, Irini Youssef, Virginia Osborn, Anna Lee, Joseph Safdieh, David Schreiber

    Prior studies have suggested that prostate-specific antigen (PSA) nadir of 0.5 ng/mL is an important surrogate endpoint for prostate cancer-specific and all-cause mortality. This study analyzed our well-followed patient cohort to assess whether this endpoint was associated with differences in prostate cancer-specific endpoints in patients receiving dose-escalated radiation. Patients with intermediate- or high-risk prostate cancer (≥T2b, or prostate-specific antigen >10 ng/mL, or Gleason score ≥7) who were treated with external beam radiation to a minimum dose of 7560 cGy +/- androgen deprivation between 2003 and 2011 were identified. Biochemical control, distant metastasis-free survival (DMFS), prostate cancer-specific survival (PCSS), and overall survival (OS) were compared between those who achieved a nadir PSA ≤0.5 ng/mL with those who did not via Kaplan-Meier analysis. Univariable and multivariable Cox regression was performed on all endpoints to assess their impact on OS. There were 367 patients identified with a median follow-up of 99.5 months. Two hundred five patients (55.9%) received androgen deprivation for a median of 24 months (range 1-81 months). Most patients (n = 308, 83.9%) achieved a nadir PSA ≤0.5 ng/mL, which was associated with improvement across all endpoints at 10 years. This included biochemical control (68.0% versus 24.0%, p < 0.001), DMFS (89.6% versus 80.8%, p = 0.019), PCSS (91.1% versus 85.7%, p = 0.01), and OS (55.7% versus 45.8%, p = 0.048). On multivariable analysis, nadir PSA >0.5 ng/mL remained strongly associated with worse outcomes across all endpoints. Achievement of nadir PSA ≤0.5 ng/mL after completion of dose-escalated radiation therapy was associated with improvement of all prostate cancer endpoints.


  • Patterns of care and outcomes of adjuvant therapy for high‐risk head and neck cancer after surgery

    by Virginia Wedell Osborn, Babak Givi, Justin Rineer, Dylan Roden, Niki Sheth, Ariel Lederman, Evangelia Katsoulakis, Kenneth Hu, David Schreiber

    Background: Postoperative chemoradiotherapy (CRT) is considered standard of care in patients with locally advanced head and neck cancer with positive margins and/or extracapsular extension (ECE).Methods: The National Cancer Data Base (NCDB) was queried to identify patients with squamous cell carcinoma of the head and neck with stages III to IVB disease or with positive margins and/or ECE diagnosed between 2004 and 2012 receiving postoperative radiotherapy (RT). Using univariable and multivariable logistic and Cox regression, we assessed for predictors of CRT use and covariables impacting overall survival (OS), including in a propensity‐matched subset.Results: Of 12 224 patients, 67.1% with positive margins and/or ECE received CRT as well as 54.0% without positive margins and/or ECE. The 5‐year OS was 61.6% for RT alone versus 67.4% for CRT. In the propensity‐matched cohort, OS benefit persisted with CRT, including in a subset with positive margins and/or ECE but not without.Conclusion: Postoperative CRT seems underutilized with positive margins and/or ECE and overutilized without positive margins and/or ECE. The CRT was associated with improved OS but the benefit persisted only in the subset with positive margins and/or ECE.


  • Open Access

    Stereotactic Body Radiation Therapy for Spinal Malignancies

    by Virginia W. Osborn, Anna Lee, Yoshiya Yamada

    Stereotactic body radiation therapy and stereotactic radiosurgery have become important treatment options for the treatment of spinal malignancies. A better understanding of dose tolerances with more conformal technology have allowed administration of higher and more ablative doses. In this review, the framework for approaching a patient with spinal metastases and primary tumors will be discussed as well as details on the delivery of this treatment.


  • Impact of Timing of Adjuvant Chemoradiation for Glioblastoma in a Large Hospital Database

    by Virginia W Osborn, Anna Lee, Elizabeth Garay, Joseph Safdieh, David Schreiber

    BACKGROUND: Although the standard of care for glioblastoma remains maximal safe resection followed by chemoradiation, conflicting reports have emerged regarding the importance of the time interval between these 2 treatments. OBJECTIVE: To assess whether differences in the duration between surgery and initiation of chemoradiation for glioblastoma had an impact on overall survival (OS) in a large hospital-based database. METHODS: The National Cancer Database was queried to identify patients diagnosed with glioblastoma between 2010 and 2012 treated with surgery followed by chemoradiation. Patients who received biopsy only were excluded. The time from surgery to initiation of radiation therapy was divided into 4 equal quartiles of ≤24, 25 to 30, 31 to 37, and >37 d. Patient characteristics were compared between groups using Pearson Chi Square and Fisher's Exact test. OS was analyzed via the Kaplan–Meier method and compared via the log-rank test. Univariable and multivariable Cox regression were performed to assess for impact of covariables on OS. RESULTS: A total of 11 652 patients were included in the analysis. Median duration from surgery to radiation was 30 d. On multivariable regression, black race, larger tumor, gross-total resection, methyguanine-methyl transferase (MGMT+), and treatment at an academic facility were associated with a duration >30 d. On multivariable analysis, there were no significant differences when comparing start within 24 d to 25 to 30 d (hazard ratio [HR] 0.96, 95% confidence interval [CI] 0.90-1.01, P = .13) or > 37 d (HR 0.97, 95% CI 0.91-1.03, P = .26), although a small OS improvement was seen if initiated within 31 to 37 d (HR 0.93, 95% CI 0.88-0.99, P = .02). CONCLUSION: There was no clear association between duration from surgery to initiation of chemoradiation on OS.